Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    MDVN

Delayed Quote. Delayed  - 09/23 10:00:00 pm
81.42 USD   +0.42%
09/23 PFIZER : expects to close Medivation buyout in 3Q
09/20 MEDIVATION : One of these five firms could be the next big thing in ..
09/16 PFIZER : Isle of Wight officials give $20,000 to reopen lost library..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Medivation Inc : Medivation Announces Participation at Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2013 | 10:34pm CEST

SAN FRANCISCO, CA -- (Marketwired) -- 10/28/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss third quarter 2013 financial results and provide a general business update on November 12, 2013 at 4:30 p.m. Eastern Time. A press release for the third quarter of 2013 will be released after markets close on November 12, 2013.

Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting: http://investors.medivation.com/events.cfm.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.

Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Source: Medivation

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
09/23 PFIZER : expects to close Medivation buyout in 3Q
09/20 MEDIVATION : One of these five firms could be the next big thing in the life sci..
09/16 PFIZER : Isle of Wight officials give $20,000 to reopen lost library hours
09/16 PFIZER : Hampton Roads water crossing project could further delay Fort Eustis In..
09/15 PFIZER : Council hears pitch for new police advisory board
09/14 PFIZER : Isle of Wight may change manufacturing taxes
09/14 PFIZER : Newport News Council approves Ivy Tower renovation
09/12 LAWSUIT FOR INVESTORS AGAINST TAKEOV : MDVN) Filed
09/12 PFIZER : Mass transit corridor options to be released in coming weeks
09/11 PFIZER : Hampton Roads Regional Jail names interim superintendent
More news
Sector news : Bio Therapeutic Drugs
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/24 BIOTECH : What's Next For M&A?
09/23 Google And Salesforce Target Twitter
09/22 Valeant Coming Apart
09/21 Vanquish The Political Fears By Purchasing The I-Shares Biotech ETF
09/21 Understanding Our Investing Biases - Part 2
Advertisement
Financials ($)
Sales 2016 907 M
EBIT 2016 336 M
Net income 2016 -279 M
Finance 2016 217 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 47,31
EV / Sales 2016 14,7x
EV / Sales 2017 11,2x
Capitalization 13 510 M
More Financials
Chart MEDIVATION INC
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Full-screen chart
Technical analysis trends MEDIVATION INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 77,2 $
Spread / Average Target -5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David T. Hung President, Chief Executive Officer & Director
Kim D. Blickenstaff Chairman
Marion McCourt Chief Operating Officer
Jennifer Jarrett Chief Financial Officer
Mohammad Hirmand Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC68.43%13 510
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
CELGENE CORPORATION-8.63%84 821
REGENERON PHARMACEUTIC..-24.40%43 212
VERTEX PHARMACEUTICALS..-27.97%22 456
More Results